0000819050-20-000040.txt : 20200318 0000819050-20-000040.hdr.sgml : 20200318 20200318161434 ACCESSION NUMBER: 0000819050-20-000040 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200318 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200318 DATE AS OF CHANGE: 20200318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Brickell Biotech, Inc. CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21088 FILM NUMBER: 20724687 BUSINESS ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (720) 505-4755 MAIL ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: VICAL INC DATE OF NAME CHANGE: 19940211 8-K 1 a20191231-8ker.htm 8-K Document
false0000819050 0000819050 2020-03-18 2020-03-18


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 8-K 
________________

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest reported) March 18, 2020
________________
BRICKELL BIOTECH, INC.
(Exact name of Registrant as specified in its charter)
Delaware
 
000-21088
 
93-0948554
(State or Other Jurisdiction
of Incorporation)
 
(Commission File
Number)
 
(IRS Employer
Identification No.)

5777 Central Avenue
Suite 102
Boulder, CO 80301
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (720) 505-4755
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common stock, par value $0.01 per share
 
BBI
 
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 





Item 2.02. Results of Operations and Financial Condition.

On March 18, 2020, Brickell Biotech, Inc., issued a press release announcing, among other things, its unaudited financial results for the three months and year ended December 31, 2019.  A copy of the press release is attached as Exhibit 99.1 to this Current Report.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1     Press release issued by Brickell Biotech, Inc., on March 18, 2020.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: March 18, 2020
Brickell Biotech, Inc.
 
 
 
 
 
 
By:
/s/ Robert B. Brown
 
 
Name:
Robert B. Brown
 
 
Title:
Chief Executive Officer
 



 EX-99.1 2 a20191231-8kex991.htm EXHIBIT 99.1 Exhibit

Exhibit 99.1

logo.jpg

Brickell Biotech Reports Fourth Quarter and Full Year 2019
Financial Results and Provides Corporate Update

BOULDER, CO — March 18, 2020 —Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.

“Becoming a public company through the listing on the Nasdaq was a significant milestone for the Company this past year,” commented Robert Brown, Chief Executive Officer of Brickell. “We remain enthusiastic about the potential for sofpironium bromide as a drug candidate to potentially improve the quality of life of the 10 million U.S. patients that suffer from primary axillary hyperhidrosis.”

Business and Recent Developments
•
On March 4, 2020, Brickell announced that positive results from its Asian development partner, Kaken Pharmaceutical Co. Ltd.’s (“Kaken”) Phase 3 pivotal study in Japan were selected for oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting on March 21, 2020, in Denver, CO. Due to concerns related to the novel coronavirus, the AAD canceled the conference and it is expected that there will be a forum to release the data in the near future. The presentation is expected to include the first public disclosure of efficacy and safety results from Kaken’s Phase 3 pivotal study of sofpironium bromide gel. Additionally, on January 10, 2020, Brickell announced that Kaken submitted a new drug application for approval in Japan of manufacturing and marketing for sofpironium bromide gel for primary axillary hyperhidrosis based on the positive results from this study.
•
On February 20, 2020, Brickell announced that positive results from its Phase 2b study with sofpironium bromide in patients with primary axillary hyperhidrosis were published in the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The paper, entitled “Efficacy and Safety of Topical Sofpironium Bromide Gel for the Treatment of Axillary Hyperhidrosis: A Phase 2, Randomized, Controlled, Double-Blinded Trial,” is now available online at (https://doi.org/10.1016/j.jaad.2020.02.016) and is expected to be published in a future print edition of JAAD.
•
On February 18, 2020, Brickell announced that Brickell, Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor (collectively “Bodor”) entered into a settlement agreement and an amended license agreement. This resolved the litigation dispute disclosed on October 23, 2019 related to the sofpironium bromide license agreement and allows Brickell to continue its efforts to develop sofpironium bromide for the treatment of hyperhidrosis.
•
On February 18, 2020, Brickell announced entry into a purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), a long-only Chicago-based institutional investor, whereby LPC purchased $2.0 million in Brickell common stock and warrants. Additionally, Brickell and LPC entered into a separate purchase agreement whereby Brickell, for up to a 36-month period, will have the right, in its sole discretion subject to satisfaction of certain conditions, to sell up to an additional $28 million of its common stock to LPC.
•
In January 2020, the last patient completed the Phase 3 long-term safety study for sofpironium bromide. Brickell remains on track to report top-line results in the second quarter of 2020. To date, there have been 19 clinical studies conducted by Brickell and Kaken of sofpironium bromide gel that encompass over 1,300 subjects.
•
On January 19, 2020, Brickell presented the results from pharmacokinetics and long-term safety extension trials with sofpironium bromide gel, 15% in pediatric patients (ages 9 to <17) with primary axillary hyperhidrosis at the Dermatology, Aesthetic & Surgical Conference. Pharmacokinetic analysis of sofpironium bromide did not show any evidence of drug or major metabolite accumulation. Pharmacokinetic findings were consistent with previous investigational evaluations in adults in which systemic sofpironium and its major metabolite concentrations were also variable, sporadic, and minimal. Sofpironium bromide was safe and well-tolerated in over 24 weeks of treatment in this clinical trial. The majority of pediatric subjects had no treatment-emergent adverse events, and there were no severe or serious adverse events. Additionally, while not designed as an efficacy study, clinically meaningful improvement, i.e., change of -1.00 point on a 5-point patient-reported outcome measures; Hyperhidrosis Disease


Severity Measure-Axillary (HDSM-Ax), were reported as early as Day 8 and improved through week 24 in this pediatric patient population. The median change in the HDSM-Ax from baseline to week 24 of was -2.10 (mean: -1.91; standard deviation: 1.038).
Financial Results
Fourth Quarter 2019 Financial Results
Cash, cash equivalents, and marketable securities were $11.7 million as of December 31, 2019 compared to $8.1 million as of December 31, 2018. In addition, Brickell has prepaid third-party clinical research organizations $4.9 million in anticipation of commencing the pivotal Phase 3 clinical trials of sofpironium bromide.

Revenue was $0.7 million for the fourth quarter of 2019 compared to $2.5 million for the fourth quarter of 2018. The decrease is primarily due to the completion of certain research and development activities by the first half of 2019 for which funding was provided under the license agreement with Kaken.

Research and development expenses were $6.6 million for the fourth quarter of 2019 compared to $4.4 million for the fourth quarter of 2018. This increase is primarily due to the additional clinical study activities and drug supply costs associated with sofpironium bromide.

General and administrative expenses were $4.9 million for the fourth quarter of 2019 compared to $1.7 million for the fourth quarter of 2018. This increase includes $1.0 million in legal settlement accrual, $0.7 million in added fees for accounting, auditing, and legal services, including litigation-related costs, $0.7 million in impairment expense, $0.5 million in insurance and rent expense, and $0.3 million in stock compensation expense and increased headcount.
Brickell’s net loss was $10.9 million for the fourth quarter of 2019 compared to $3.7 million for the fourth quarter of 2018.
Full Year 2019 Financial Results
Revenue was $7.9 million for the year ended December 31, 2019 compared to $10.9 million for the year ended December 31, 2018. The decrease is primarily due to the recognition in 2018 of a $5.0 million payment from Kaken.
Research and development expenses were $20.2 million for the year ended December 31, 2019 compared to $13.0 million for the year ended December 31, 2018. This increase is primarily due to the additional clinical study activities, including the Phase 3 long-term safety study, and drug supply costs associated with sofpironium bromide.
General and administrative expenses were $12.2 million for the year ended December 31, 2019 compared to $6.4 million for the year ended December 31, 2018. This increase includes $4.1 million in added fees for accounting, auditing, and legal services, including Merger-related costs, $1.0 million in stock compensation expense and increased headcount, $1.0 million in legal settlement accrual, and $0.7 million in impairment expense, partially offset by a decrease of $1.0 million in sub-licensing fees.
Brickell’s net loss was $23.9 million for the year ended December 31, 2019 compared to $9.2 million for the year ended December 31, 2018.
Conference Call and Webcast Information
Brickell’s management will host a conference call today at 4:30 p.m. ET to discuss the financial results and recent corporate developments. The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID #13700118. A live webcast of the conference call can be accessed through the “Investors” tab on the Brickell Biotech website at http://www.brickellbio.com. A replay will be available on this website shortly after conclusion of the event for 90 days.
About Sofpironium Bromide
Sofpironium bromide is a proprietary new molecular entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly


metabolized into a less active metabolite once absorbed into the blood. This proposed mechanism of action may allow for highly effective doses to be used while limiting systemic side effects. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida. Sofpironium bromide is not approved for use in any country at this time.

About Hyperhidrosis

Hyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States and more than 16 million people, or 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States or 10 million individuals and an estimated 45% of patients with hyperhidrosis in Japan or 7.2 million individuals1,2.

About Brickell

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit http://www.brickellbio.com.

Cautionary Note Regarding Forward-Looking Statements

Any statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of future clinical trials and prospects for commercializing any of Brickell’s product candidates, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Brickell, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, potential delays for any reason in product development, regulatory changes, unanticipated demands on cash resources and risks associated with developing, and obtaining regulatory approval for and commercializing novel therapeutics.

Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at http://www.sec.gov (or at http://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.










                                 
1 Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.
2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.


Brickell Biotech, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
 
Three Months Ended
December 31,
 
Year Ended
December 31,
 
2019
 
2018
 
2019
 
2018
 
(unaudited)
 
 
 
 
Collaboration revenue
$
669

 
$
2,473

 
$
7,917

 
$
10,888

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Research and development
6,629

 
4,389

 
20,214

 
12,960

General and administrative
4,881

 
1,685

 
12,171

 
6,379

Total operating expenses
11,510

 
6,074

 
32,385

 
19,339

Loss from operations
(10,841
)
 
(3,601
)
 
(24,468
)
 
(8,451
)
Investment and other income, net
93

 
16

 
157

 
61

Gain on extinguishment
—

 
—

 
2,318

 
—

Interest expense
(114
)
 
(321
)
 
(2,096
)
 
(1,090
)
Change in fair value of derivative liability
—

 
—

 
(11
)
 
—

Change in fair value of warrant liability
—

 
236

 
223

 
244

Net loss
(10,862
)
 
(3,670
)
 
(23,877
)
 
(9,236
)
Reduction (accretion) of redeemable convertible preferred stock to redemption value
—

 
(865
)
 
10,274

 
(5,936
)
Net loss attributable to common stockholders
$
(10,862
)
 
$
(4,535
)
 
$
(13,603
)
 
$
(15,172
)
Net loss per share attributable to common stockholders, basic and diluted
$
(1.38
)
 
$
(7.72
)
 
$
(4.50
)
 
$
(25.85
)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted
7,890,823

 
587,763

 
3,023,023

 
586,969



Brickell Biotech, Inc.
Selected Financial Information
Condensed Consolidated Balance Sheet Data
(amounts in thousands)
 
December 31,
 
2019
 
2018
Cash and cash equivalents
$
7,232

 
$
8,067

Marketable securities, available-for-sale
4,497

 
—

Prepaid expenses and other current assets
6,240

 
204

Total assets
18,144

 
8,749

Note payable
—

 
4,639

Total liabilities
10,570

 
22,077

Total stockholders’ equity (deficit)
7,574

 
(71,618
)


Brickell Investor Contact:
Patti Bank
Managing Director, Westwicke
IR@brickellbio.com


 EX-101.SCH 3 bbi-20200318.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 bbi-20200318_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 bbi-20200318_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bbi-20200318_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 bbi-20200318_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 logo.jpg begin 644 logo.jpg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end EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -"!X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ T(%R4"?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " #0@7)0>VA$>>X K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>*$Y&*2;U9:6G#08K;.QF;+4UBV-C:R1]^R5> MFS*V!]C1TN]/GT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2.27ZJ7GP MT2F:GO$(0>D/=42HJVH%#DD910IF8!$6(I.MT4)'5.3C!6_T@@^?L&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#DW.33MP M>'MZ?,GK%K9/I'J-TZ]D!9T#;MAU\FOSL-WOF*RKNBJJIN#K/5\)?B_X^GUV M_>%W$W;>V(/]Q\970=G"K[N07U!+ P04 " #0@7)0F5R<(Q & "<)P M$P 'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03 M621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS M[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C( MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU M+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=* MY \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_ MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R MSTS0LS0[=R M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2 M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE ML<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7G MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5 M' 86%S+D4.Z2D 83 >LX=SFWJXPD6L_UC6'ODR MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\ MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\! M4$L#!!0 ( -"!&PO=V]R:W-H965T&UL=5;MCILP$'P5Q ,ZLO5N(5L6W7LPG]R\ZO;*SO+IBJGNN&MKF6;*'[>I)_(>D=GCN 1 MKS7O]<,X<4SESI^Y$*Z2W<>?L6@Z:3KBX_BC M^A=_>'N8 ]/\68K?]_9S6N[>M_F579W94;$;D#0!P29$)FM/0E05(!Z M>O% ISB]0.F%IYT8)N([P0-.8'YIZ#R&B5A/ M\)03&&(:FH]A8N[C42?(M_NL/U ,%%?\.Q3F.LR?),Q3.1_C.+9IS#7 M9?B.(1APENRA&ULA551;]HP$'[N?L4)[6&3@#B4C'2B2!#2 M+2H%5B)-VIN;F,1:8F>V0^'?[X!VDV+2/B7Q???=W7?GRUAK [7@?VH6R%J8 MV\YPV(%]60A]V\F-J;XZCDYR5E+=EQ43:-E*55*#GRIS=*48377.F"D+9T#( M%Z>D7'0F8\TG8S,)Y(XI6-.,C1TS&3O'T[/E@:H^N'X7!F1 FL:S6X5N_:9I M+I.Z9,) ?*@L4K]WWXI?,\5E"J%(84Y-:SX?KJXN910*P\T!'EG&M5$4^9:T MM$AFCU%P'RX6,(M6<1A\[T*T#*P27K@BD4A5244-EZ(+&X-9@51PZH,ZX#.U M LS#%K([7C!8UN434TT$(:0W<(GOM[C&= ]1BA+Q+4].R;00W5SWR,W0][QA M"],T3173NOOZ @LN&*R$588W&HT@P)"*%C#=,5%;D# M47#\0IEC^2RL_LFZ2.W"FQ3_6K56'(\YKG/Q4WA@D,5):X'OH,&Y;46-#!7C-EB=.NC4Q^=W'=*-C1HF;PD?2)"Q6RZYPJJ\)8 MT?18WN90/DFKN-DLLB1YB0_A/LFIR-C%Y;&<;N;3'RV#$Y9,9<>@WY1\-OFQ M,1455D4OZ->K%:%$>[AG%@YW O'=&^)9,S-%C=.3SG<%S?Y;'?Q13/X"4$L# M!!0 ( -"!&POC"@J"RL.?!U[2=MH'<3*?'=G^]2=/;T0?QX(.^-#/? M3+[YGTP!07FA:9'M23PIY49M"8TQ-E1=88O2-W- (^E2L@%RYS^LBE*)V8 M<[D2BF0TR0@_6L,)]$+*A<>);1Q 62Q0OR62_I/@=7KO2ND MW 2F- )%9CDB./WDG3EY!G\)D<4^3]8K;!V?DO2>[A/FP1S'A13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*BT(O&3M0U M1'GAA_GUM#P0>)S6/$HQ:#>S@7WOT3Q U!+ P04 " #0@7)0+6VE:#H! G @ #P M 'AL+W=O?GE]F)^+ C.F1?UCA?JE:DF^:YKUJPVM]1!RY4 M&F*K):2\SWW'H&O? H@U^;@H)KG5Z-1\-G"M.;]-2* 2)!? "&P13OY:CVFF M0\,1/O6N5(7*="_TA$: EUK@F:GOT.U+-5)9@^QE$W>G3HL.+9ZA3IEOZ?1" MC&=RHLVF8C(F3<5"&@H;_"^R!1:L_C2*WGWHH+54DR(0'M'C#@W*=ZG2VX * M5^0W9R0?AG@Q<&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.MDD$*@S 0 +\B>4!7;>FAJ*=> MO+;]0-#5B)J$[);J[YMZ44&A!R\)8LX'LQYT4,CQT>7S%1]_276<]>@C"MA[_)1/TUP.K795]02P,$% @ MT(%R4 N/V ,A 0 5P0 !, !;0V]N=&5N=%]4>7!E&ULM51-3\,P M#/TK4Z]HS># 6V[ %>8!'\@)&X;-5^RO=']>]QN0V(J8FC;)8GS[/=>$BOS M]VT&FG3!1UH4#7-^4(I, T%3F3)$0:J$0;.$6*NL3:MK4'>SV;TR*3)$GG+/ M42SG3U#IM>?)XVZ_IUX4.F?OC&:7HMI$>T0ZW1.6"'[(H<9ENI&$8O+<"0O) MWJ(0E IU@L)Q81]+W>L&$)V%?UE+5>4,V&3604I*R@C:4@/ P9?4: 3[QNAB MO?>[TL@O.@BQZKSZD5!>SP=O/8P;&)!+*K.T!8Q)#PGPG;83UVX=\@J6$Z[];_:'29RZ!= M_,W(1TKM05\-_\GR"U!+ 0(4 Q0 ( -"!D !D;V-0&UL4$L! M A0#% @ T(%R4'MH1'GN *P( !$ ( !F0$ &1O M8U!R;W!S+V-O&UL4$L! A0#% @ T(%R4)E&PO=V]R:W-H M965T&UL4$L! A0#% @ T(%R4%X*=BQ> @ +@8 !0 M ( !UPL 'AL+W-H87)E9%-T&UL4$L! A0#% M @ T(%R4+JA.8K7 0 ,@8 T ( !9PX 'AL+W-T>6QE M&PO=V]R:V)O;VLN>&UL4$L! A0#% @ T(%R4/_ )@B] MA0( !H ( !T!$ 'AL+U]R96QS+W=O ZIP 11 0000819050-20-000040-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000819050-20-000040-xbrl.zip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htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page
Mar. 18, 2020
Cover page.  
Document Type 8-K
Document Period End Date Mar. 18, 2020
Entity Registrant Name BRICKELL BIOTECH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 000-21088
Entity Tax Identification Number 93-0948554
Entity Address, Address Line One 5777 Central Avenue
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Boulder
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80301
City Area Code 720
Local Phone Number 505-4755
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol BBI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000819050
Amendment Flag false
JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a20191231-8ker.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "bbi-20200318_cal.xml" ] }, "definitionLink": { "local": [ "bbi-20200318_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a20191231-8ker.htm" ] }, "labelLink": { "local": [ "bbi-20200318_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bbi-20200318_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bbi-20200318.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bbi", "nsuri": "http://brickellbio.com/20200318", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a20191231-8ker.htm", "contextRef": "D2020Q1Mar18-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://brickellbio.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a20191231-8ker.htm", "contextRef": "D2020Q1Mar18-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 a20191231-8ker_htm.xml IDEA: XBRL DOCUMENT 0000819050 2020-03-18 2020-03-18 false 0000819050 8-K 2020-03-18 BRICKELL BIOTECH, INC. DE 000-21088 93-0948554 5777 Central Avenue Suite 102 Boulder CO 80301 720 505-4755 false false false false Common stock, par value $0.01 per share BBI NASDAQ false XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://brickellbio.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports a20191231-8ker.htm a20191231-8kex991.htm bbi-20200318.xsd bbi-20200318_cal.xml bbi-20200318_def.xml bbi-20200318_lab.xml bbi-20200318_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 17 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}